Toker Alex
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, EC/CLS-633A, 02130, Boston, MA, USA,
Subcell Biochem. 2012;58:95-110. doi: 10.1007/978-94-007-3012-0_4.
The phosphoinositide 3-kinase (PI 3-K) signal relay pathway represents arguably one of the most intensely studied mechanisms by which extracellular signals elicit cellular responses through the generation of second messengers that are associated with cell growth and transformation. This chapter reviews the many landmark discoveries in the PI 3-K signaling pathway in biology and disease, from the identification of a novel phosphoinositide kinase activity associated with transforming oncogenes in the 1980s, to the identification of oncogenic mutations in the catalytic subunit of PI 3-K in the mid 2000s. Two and a half decades of intense research have provided clear evidence that the PI 3-K pathway controls virtually all aspects of normal cellular physiology, and that deregulation of one or more proteins that regulate or transduce the PI 3-K signal ultimately leads to human pathology. The most recent efforts have focused on the development of specific PI 3-K inhibitors that are currently being evaluated in clinical trials for a range of disease states.This chapter is devoted to a historical review of the landmark findings in the PI 3-K from its relatively humble beginnings in the early to mid 1980s up until the present day. When considering the key findings in the history of PI 3-K, it is essential to recognize the landmark studies by Lowell and Mabel Hokin in the 1950s who were the first to describe that extracellular agonists such as acetylcholine could stimulate the incorporation of radiolabeled phosphate into phospholipids (Hokin and Hokin 1953). Their work initiated an entirely new field of lipid signaling, and subsequent studies in the 1970s by Michell and Lapetina who linked phosphoinositide turnover to membrane-associated receptors that initiate intracellular calcium mobilization (Lapetina and Michell 1973). Later studies revealed that the phospholipase-mediated breakdown of the same minor membrane phospholipids such as PtdIns-4,5-P(2) (phosphatidylinositol-4,5-bisphosphate) is responsible for the release of two additional key second messengers, diacylglycerol (DG) and IP(3) (inositol-1,4,5-trisphosphate) (Kirk et al. 1981; Berridge 1983; Berridge et al. 1983). Berridge, Irvine and Schulz then revealed that one of the byproducts of this lipid signal relay pathway is the release of calcium from intracellular stores such as the endoplasmic reticulum (Streb et al. 1983). Finally, pioneering studies by Nishizuka in the late 1970s identified PKC (protein kinase C) as a phospholipid and diacylglycerol-activated serine/threonine protein kinase (Inoue et al. 1977; Takai et al. 1977). At this point, it probably seemed to most at the time that the story was complete, such that hydrolysis of phosphoinositides such as PtdIns-4,5-P(2) and PtdIns-4-P would account for the major mechanisms of agonist-stimulated lipid signaling leading to physiological responses. On the contrary, the story was far from complete and was about to become a lot more complex.
磷酸肌醇3激酶(PI 3-K)信号转导途径可以说是研究最为深入的机制之一,通过该机制,细胞外信号通过产生与细胞生长和转化相关的第二信使来引发细胞反应。本章回顾了PI 3-K信号通路在生物学和疾病领域的众多里程碑式发现,从20世纪80年代与转化癌基因相关的新型磷酸肌醇激酶活性的鉴定,到21世纪中期PI 3-K催化亚基致癌突变的鉴定。二十五年的深入研究提供了明确的证据,表明PI 3-K途径实际上控制着正常细胞生理学的所有方面,并且调节或转导PI 3-K信号的一种或多种蛋白质的失调最终会导致人类疾病。最近的努力集中在开发特定的PI 3-K抑制剂,目前这些抑制剂正在针对一系列疾病状态进行临床试验评估。本章致力于对PI 3-K从20世纪80年代初到中期相对不起眼的开端直至如今的里程碑式发现进行历史回顾。在考虑PI 3-K历史上的关键发现时,必须认识到20世纪50年代洛厄尔和梅布尔·霍金的里程碑式研究,他们是第一个描述细胞外激动剂如乙酰胆碱可以刺激放射性标记的磷酸盐掺入磷脂的人(霍金和霍金,1953年)。他们开启了脂质信号传导的全新领域,随后在20世纪70年代,米切尔和拉佩蒂纳的研究将磷酸肌醇周转与引发细胞内钙动员的膜相关受体联系起来(拉佩蒂纳和米切尔,1973年)。后来的研究表明,磷脂酶介导的相同微量膜磷脂如磷脂酰肌醇-4,5-二磷酸(PtdIns-4,5-P₂)的分解负责另外两种关键第二信使二酰基甘油(DG)和肌醇-1,4,5-三磷酸(IP₃)的释放(柯克等人,1981年;伯里奇,1983年;伯里奇等人,1983年)。伯里奇、欧文和舒尔茨随后揭示,这种脂质信号转导途径的副产物之一是从内质网等细胞内储存库中释放钙(斯特雷布等人,1983年)。最后,20世纪70年代末西冢的开创性研究将蛋白激酶C(PKC)鉴定为一种磷脂和二酰基甘油激活的丝氨酸/苏氨酸蛋白激酶(井上等人,1977年;高井等人,1977年)。在这一点上,当时大多数人可能觉得这个故事已经完整了,以至于磷脂酰肌醇如PtdIns-4,5-P₂和PtdIns-4-P的水解将解释激动剂刺激的脂质信号传导导致生理反应的主要机制。相反,这个故事远未完整,而且即将变得更加复杂。